Trials
Search / Trial NCT06435962

Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple

Launched by ASSIUT UNIVERSITY · May 29, 2024

Trial Information

Current as of February 19, 2025

Not yet recruiting

Keywords

ClinConnect Summary

Multiple sclerosis (MS) is one of the leading disabling neurological diseases in young Adults. Characteristically reliable biomarkers for every independent MS pathogenic factor are extremely important.

1 Increasing evidence has demonstrated that neuronal and axonal damage within the central nervous system (CNS) contributes substantially to the development of permanent disability in patients with MS

* 2 Thus, reliable, economic and easily assessable complementary surrogate biomarkers for axonal Degeneration and consequently disability remain to be identified
* 3 The optic nerve can serve a...

Gender

ALL

Eligibility criteria

  • 1. inclusion criteria
  • 1. both sex
  • 2. Age group from 15 to 50 yrs
  • 3. Patient with RRMS without history of optic neuritis
  • 2. Exclusion criteria :
  • 1. History of previous optic neuritis
  • 2. Medical illness of eye(e.g. diabetes and hypertension)
  • 3. MS patient on fingolimod for 6 months or more
  • 4. Relapsing or use of steroid in the past 3 months
  • 5. Proved alternative diagnosis (neuromyelitis optica )
  • 6. local eye disease or surgery

Trial Officials

Anwar M Ali, professor

Study Director

Assiut University

About Assiut University

Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0